
Quarterly Result2 Nov 2026, 05:30 pm
Akums Drugs Declares Unaudited Q2 FY27 Results
AI Summary
Akums Drugs and Pharmaceuticals Limited announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The Board of Directors approved these results at a meeting held on November 02, 2026. The company also stated that 100% of the Initial Public Offer proceeds have been fully utilized, thus exempting them from submitting future statements of deviation or variation. Additionally, Mr. Sanjay Kumar, President – Operations, has been designated as Senior Management Personnel.
Key Highlights
- Unaudited standalone and consolidated results declared.
- Results for the quarter and half-year ended September 30, 2026.
- IPO proceeds fully utilized; no future deviation statements needed.
- Mr. Sanjay Kumar appointed as Senior Management Personnel.
Price Impact
More from AKUMS